Lung Cancer Clinical Trial
Official title:
A Randomized Controlled Trial To Determine If Thoracoscopic Resection Of Subcentimetre Lung Nodules After Localization Using Percutaneously Inserted Platinum Microcoils Under CT Guidance Reduces Rate Of Conversion To Open Thoracotomy From 50% To 10%
| Verified date | July 2012 |
| Source | University of British Columbia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Health Canada |
| Study type | Interventional |
LAY ABSTRACT
1. Statement of the health problem or issue: Of the estimated 24,000 Canadians who will be
diagnosed with lung cancer in 2008, 21,000 will die of their disease. Based on this
cancer incidence and survival data, the most promising current strategy for improving
outcome is screening and early detection. It is suggested that if lesions are
discovered at an earlier stage of disease, they will have a higher likelihood of being
treatable and therefore, survival will be improved. CT detection of growing small lung
nodules, many of which are non-cancerous (benign), raises the possibility of lung
cancer and thus causes anxiety in patients and referring clinicians. Unfortunately,
confident separation of benign from malignant small lung nodules cannot be reliably
achieved using CT or PET criteria. Pathologic diagnosis using needle or excision biopsy
is usually required.
Excision biopsy removes the entire nodule at one setting and eliminates the sampling
error associated with needle biopsy, making it appealing to physicians and patients. To
reduce post-operative pain and breathing difficulties, excision biopsy is often
performed using minimally invasive surgery (video assisted thoracoscopic surgery,
VATS). Finding small pulmonary nodules is often difficult with the minimally invasive
camera (VATS) and a bigger incision (thoracotomy) is necessary in more than 60% of our
patients.
We recently developed a technique of using platinum micro-coils, which are inserted in
the lung nodule using CT guidance, to locate the nodule with fluoroscopy and then
excise it with VATS. We have completed a pilot study (n=75 nodules; 69 patients) to
determine the effectiveness of this technique. Seventy three (97%) 4-24-mm nodules were
successfully removed at fluoroscopically guided VATS excision.
2. Objective of your project: To improve our ability to successfully excise small growing
lung nodules with minimally invasive VATS surgery using CT guided micro-coil
localization techniques.
3. How will you undertake your work? We propose to conduct a randomized controlled trial
to determine if the use of CT guided platinum microcoil markers for VATS excision of
subcentimetre pulmonary nodules can reduce the rate of conversion to open thoracotomy
from 50% to 10%.
4. What is unique/innovative about your project? New image guided minimally invasive
surgical technique for removing early growing cancers was developed at the Vancouver
General Hospital and the University of British Columbia. This has been published in
peer-reviewed journals and can potentially allow us to accurately locate and excise
suspicious lung nodules
5. Relevance to Lung Association's mission statement? Lung cancer remains a major health
problem in Canada. Early detection and screening programs allow for discovery of
nodules when they are still very small and therefore, likely curable. Excision biopsy
removes the entire nodule at one setting and eliminates the sampling error associated
with needle biopsy, making it appealing to patients and physicians. To reduce post
operative morbidity, costs and volume of lung removed, excision biopsy is often
performed using video assisted thoracoscopic surgery (VATS) techniques. Using a pilot
project grant from the BC Lung Association we have developed a new technique that
allows preoperative CT marking of the nodule and minimally invasive removal of the
lesion. We hope that this technique will allow earlier treatment of lung cancers and
improve survival in this devastating disease.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | October 2013 |
| Est. primary completion date | June 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 19 Years and older |
| Eligibility |
Inclusion Criteria: Patients will be evaluated for eligibility using the following
criteria: - All newly diagnosed patients with small lung nodules < 1cm that require excision with no history of prior ipsilateral thoracotomy. - The nodules must be located in parts of the lung that are amenable to thoracoscopic wedge excision of the nodules.The external surface of the lesion must be at least 2 cm from the major pulmonary arteries, veins, and main bronchi to allow safe and adequate thoracoscopic excision of the lesion. - Patients must be mentally competent to give written, informed consent - Patients must be capable of independently completing standard English-language QOL instruments. Exclusion Criteria: - Patients will be excluded from the trial if they do not consent to participate in the study, or if the radiologist and surgeon agree that the nodule is located too centrally to be safely excised using thoracoscopic wedge techniques. - Patients with more than three nodules will be excluded from the study. - Patients with a positive diagnosis of non-small cell lung cancer obtained from sputum cytology, bronchoscopy, or CT guided needle biopsy will be excluded from the study. - If the patient is excluded, he/she will receive the current standard treatment, which may include needle biopsy, continued observation of the nodule at three to six monthly intervals, or excisional surgery (thoracoscopy or open thoracotomy). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Canada | Vancouver General Hospital - Diamond Pavilion | Vancouver | British Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| University of British Columbia |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | conversion to open thoracotomy | final surgery June15, 2012 | No | |
| Secondary | the quality of life using well-validated quality of life instruments | last date July 15, 2013 | No | |
| Secondary | the preoperative, intraoperative and postoperative costs | end: July 15, 2013 | No | |
| Secondary | the perioperative morbidity and mortality | last date June 15, 2012 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|